Affordable Access

deepdyve-link
Publisher Website

Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach.

Authors
  • González-Calle, Verónica1
  • Keane, Niamh1
  • Braggio, Esteban1
  • Fonseca, Rafael2
  • 1 Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ.
  • 2 Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ. Electronic address: [email protected]
Type
Published Article
Journal
Clinical Lymphoma Myeloma & Leukemia
Publisher
Elsevier
Publication Date
Oct 01, 2017
Volume
17
Issue
10
Pages
621–630
Identifiers
DOI: 10.1016/j.clml.2017.06.021
PMID: 28743429
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Recently, large sequencing studies have provided insights into the mutational landscape of multiple myeloma (MM), identifying actionable mutations and giving a precious opportunity for exploring new targeted therapies. The main goal of precision medicine, matching patients with the right drug, seems to be closer than ever. However, no targeted therapies in MM are approved yet. Several clinical trials testing targeted drugs and enrolling patients with MM are currently ongoing and will provide predictive biomarkers that might support clinical decision making. In this review, we evaluate the evidence supporting the implementation of precision medicine in MM and we discuss the challenges that should be dealt with in this imminent and promising new era. Copyright © 2017 Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times